SINGLE CHAIN PROTEINS WITH C-TERMINAL MODIFICATIONS

• US 20140161796A1
• Filed: 09/13/2013
• Published: 06/12/2014
• Est. Priority Date: 09/13/2012
• Status: Abandoned Application

• Current Assignee: Novartis Ag
• Original Assignee: Andreas Loew, Hilmar Ebersbach
• Inventors: LOEW, Andreas, EBERSBACH, Hilmar
• Application Number:
  US14/026,599
• Publication Number:
  US 20140161796A1
• Time in Patent Office: Days
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/40 characterized by post-translational modification
• CPC Class Codes: C07K 2317/569 Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
• CPC Class Codes: G01N 33/5306 Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding

Abstract

The invention pertains to an isolated V_H single domain antibody comprising a C-terminal modification, where the C-terminal modification comprises a deletion of at least one amino acid residue that eliminates the interaction of a pre-existing antibody with the single domain antibody without interfering with the binding of the single domain antibody with its target.

Claims

1. An isolated V_H single domain antibody comprising a C-terminal modification, wherein the C-terminal modification comprises a deletion of at least one amino acid residue such that the deletion of at least one amino acid residue in the single domain antibody eliminates the interaction of a pre-existing antibody with the single domain antibody without interfering with the binding of the single domain antibody with its target.

2. The isolated single domain antibody of claim 1, wherein the C-terminal of the single domain antibody is exposed such that the exposed C-terminal is available for interaction with the pre-existing antibody, and wherein the C-terminal modification reduces the exposure of the C-terminal to the pre-existing antibody.

3. The isolated single domain antibody of claim 1, wherein the C-terminal modification modifies the C-terminus of the single domain antibody by a mechanism selected from the group consisting of eliminating the interaction of the pre-existing antibody by altering the three dimensional configuration of the C-terminal single domain antibody such that the pre-existing antibody no longer recognizes the single domain antibody, alters the exposure of the C-terminal single domain antibody to the pre-existing antibody, alters the steric hindrance between the single domain antibody and the pre-existing antibody, disrupts at least one conformational neoepitope in the C-terminus, and shields at least one neoepitope in a framework of the single domain antibody.

4. The isolated single domain antibody of claim 1, wherein the single domain antibody is a human V_H.

5. The isolated single domain antibody of claim 4, wherein the human V_H is selected from the group consisting of SEQ ID NO:

8, SEQ ID NO;

9, SEQ ID NO;

10, SEQ ID NO;

11, SEQ ID NO;

12, and SEQ ID NO;

13.

6. The isolated single domain antibody of claim 1, wherein the amino acid residue is selected from the group consisting of a naturally occurring amino acid or a non-naturally occurring amino acid.

7. The isolated single domain antibody of claim 1, wherein the C-terminal modification further comprises the deletion of at least one additional amino acid residue from the C-terminus of the single domain antibody.

8. The isolated single domain antibody of claim 1, wherein the C-terminal modification further comprises the deletion of at least two additional amino acid residues from the C-terminus of the single domain antibody.

9. The isolated single domain antibody of claim 1, wherein the C-terminal modification further comprises the deletion of at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine additional amino acid residues from the C-terminus of the single domain antibody.

10. The isolated single domain antibody of claim 1, wherein the C-terminal modification is the deletion of an amino acid sequence selected from the group consisting of Arg, Arg-Thr, Arg-Thr-Val, Gly-Gln, and Gly-Gln-Pro.

11. The isolated single domain antibody of claim 1, wherein the C-terminal modification eliminates a pre-existing antibody response at least by about 10% compared with an single domain antibody without the C-terminal modification.

12. The isolated single domain antibody of claim 1, wherein the V_H comprises SEQ ID NO:

8, and wherein the C-terminal modification comprises a deletion of one amino acid to three amino acids.

13. The isolated single domain antibody of claim 1, wherein the V_H comprises SEQ ID NO:

9, and wherein the C-terminal modification comprises a deletion of one amino acid to three amino acids.

14. The isolated single domain antibody of claim 1, wherein the V_H comprises SEQ ID NO:

10, and wherein the C-terminal modification comprises a deletion of one amino acid to three amino acids.

15. The isolated single domain antibody of claim 1, wherein the V_H comprises SEQ ID NO:

11, and wherein the C-terminal modification comprises a deletion of one amino acid to three amino acids.

16. The isolated single domain antibody of claim 1, wherein the V_H comprises SEQ ID NO:

12, and wherein the C-terminal modification comprises a deletion of one amino acid to three amino acids.

17. The isolated single domain antibody of claim 1, wherein the V_H comprises SEQ ID NO:

13, and wherein the C-terminal modification comprises a deletion of one amino acid to three amino acids.

18. A nucleic acid encoding a composition of claim 1.

19. An expression vector comprising the nucleic acid of claim 18.

20. A host cell or organism comprising the expression vector of claim 19.

21. A pharmaceutical composition comprising the single domain antibody of claim 1.

25. The method of claim 18, wherein the human sample is selected from the group consisting of blood and serum.

22. A method of eliminating a pre-existing immune response in a subject comprising:

administering a single domain antibody comprising a C-terminal modification, wherein the C-terminal modification comprises a deletion of at least one amino acid residue such that the deletion of at least one amino acid residue to the single domain antibody eliminates the interaction of a pre-existing antibody with the single domain antibody without interfering with the binding of the single domain antibody with its target.

23. A method of improving a response to single domain antibody in a subject having a pre-existing antibody against a single domain antibody, comprising:

administering single domain antibody comprising a C-terminal modification, wherein the C-terminal modification comprises a deletion of at least one amino acid residue such that the deletion of at least one amino acid residue to the single domain antibody eliminates the interaction of a pre-existing antibody with the single domain antibody without interfering with the binding of the single domain antibody with its target.

24. A method of predicting whether a pre-existing antibody will produce a pre-existing immune response with a single domain antibody comprising:

contacting the single domain antibody with a human sample;

determining whether a pre-existing antibody, if present in the human sample, binds to the single domain scaffold; and

modifying the C-terminal region of single domain antibody by the deletion of at least one amino acid residue such that the C-terminal modification eliminates the interaction of the pre-existing antibody with the single domain antibody.